Company News: Page (1) of 1 - 12/11/17

email article

print page

Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Application seeks approval of the XARELTO® vascular dose (2.5mg BID) to reduce the risk of major cardiovascular events in patients with chronic CAD and/or PAD, and to reduce the risk of acute limb isc...
(December 11, 2017) This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:CAD,CAD/CAM/CAE,England,USA, Inc.,Medicine,Disease,Surgery,medical technologists,Pregnancy,Dental,Surgery,Medication,Vitamins/Nutrition,Womens Health,Pregnancy,Physician,Health Technologist,Science,Medical,Science,england,Other,
Related Sites: AEC Newsroom ,   Digital CAD ,   Oceania ,   DMN Newswire ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: CADList Newsletter ,   Tutorial Finder ,   Review Seeker

---